Ascletis Pharma Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug $(IND.AU)$ application for a Phase I trial of ASC50, an oral small molecule inhibitor targeting interleukin-17 (IL-17), for the treatment of mild-to-moderate plaque psoriasis. ASC50, discovered and developed in-house by Ascletis, demonstrated favorable preclinical characteristics, including higher drug exposure, longer half-life, and lower clearance in non-human primates compared to existing oral IL-17 inhibitors. The company plans to begin dosing in the Phase I trial during the third quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.